Five-year probability of survival (and 95% confidence intervals) of patients classified into IPSS-R categories and stratified according to age, HCT-CI, presence of monosomal karyotype, and response to induction therapy
| Variable . | 5-year probability of survival after allogeneic HSCT . | ||||
|---|---|---|---|---|---|
| IPSS-R low risk . | IPSS-R intermediate risk . | IPSS-R high risk . | IPSS-R very high risk . | P . | |
| Age | |||||
| <50 years | 79% (55-91) | 60% (43-72) | 42% (29-51) | 30% (20-40) | .006 |
| n = 36 | n = 51 | n = 112 | n = 87 | ||
| ≥50 years | 59% (29-75) | 54% (41-74) | 36% (25-51) | 14% (7-23) | .002 |
| n = 23 | n = 38 | n = 95 | n = 77 | ||
| HCT-CI* | |||||
| Low/intermediate risk | 94% (69-99) | 59% (45-71) | 48% (35-58) | 27% (17-37) | <.001 |
| n = 27 | n = 59 | n = 110 | n = 106 | ||
| High risk | — | 31% (5-51) | 29% (6-54) | 15% (4-35) | NS |
| n = 11 | n = 13 | n = 18 | |||
| Monosomal karyotype | |||||
| No | 71% (55-81) | 58% (47-68) | 39% (31-47) | 27% (20-35) | .001 |
| n = 59 | n = 87 | n = 182 | n = 115 | ||
| Yes | — | — | 18% (7-49) | 0% (0-21) | NS |
| n = 25 | n = 49 | ||||
| Response to induction therapy | |||||
| Complete remission | — | — | 41% (27-58) | 23% (12-43) | .035 |
| n = 62 | n = 37 | ||||
| Active disease | — | — | 27% (8-41) | 16% (7-25) | .011 |
| n = 41 | n = 73 | ||||
| Variable . | 5-year probability of survival after allogeneic HSCT . | ||||
|---|---|---|---|---|---|
| IPSS-R low risk . | IPSS-R intermediate risk . | IPSS-R high risk . | IPSS-R very high risk . | P . | |
| Age | |||||
| <50 years | 79% (55-91) | 60% (43-72) | 42% (29-51) | 30% (20-40) | .006 |
| n = 36 | n = 51 | n = 112 | n = 87 | ||
| ≥50 years | 59% (29-75) | 54% (41-74) | 36% (25-51) | 14% (7-23) | .002 |
| n = 23 | n = 38 | n = 95 | n = 77 | ||
| HCT-CI* | |||||
| Low/intermediate risk | 94% (69-99) | 59% (45-71) | 48% (35-58) | 27% (17-37) | <.001 |
| n = 27 | n = 59 | n = 110 | n = 106 | ||
| High risk | — | 31% (5-51) | 29% (6-54) | 15% (4-35) | NS |
| n = 11 | n = 13 | n = 18 | |||
| Monosomal karyotype | |||||
| No | 71% (55-81) | 58% (47-68) | 39% (31-47) | 27% (20-35) | .001 |
| n = 59 | n = 87 | n = 182 | n = 115 | ||
| Yes | — | — | 18% (7-49) | 0% (0-21) | NS |
| n = 25 | n = 49 | ||||
| Response to induction therapy | |||||
| Complete remission | — | — | 41% (27-58) | 23% (12-43) | .035 |
| n = 62 | n = 37 | ||||
| Active disease | — | — | 27% (8-41) | 16% (7-25) | .011 |
| n = 41 | n = 73 | ||||
HCT-CI as defined by Sorror et al.22